Use: Labeled indications
- Rocuronium Bromide Injection is indicated as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical…
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Rocuronium Bromide Injection is indicated as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Rocuronium Bromide Injection is a nondepolarizing neuromuscular blocking agent indicated as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. (1)
Contraindications
4 CONTRAINDICATIONS Rocuronium Bromide Injection is contraindicated in patients known to have hypersensitivity (e.g., anaphylaxis) to rocuronium bromide or other neuromuscular blocking agents [see Warnings and Precautions (5.2)]. Hypersensitivity (e.g., anaphylaxis) to rocuronium bromide or other neuromuscular blocking agents. (4)
US FDA labelDosing: Adult
- Rocuronium Bromide Injection is for intravenous use only. Rocuronium Bromide Injection should only be administered by experienced clinicians or trained individuals supervised by an experienced clinician familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents. (2.1)
- Individualize the dose for each patient. (2.1)
- Peripheral nerve stimulator recommended for determination of drug response and need for additional doses, and to evaluate recovery. (2.1)
- Store Rocuronium Bromide Injection with tamper evidence cap and ferrule intact and in a manner that minimizes the possibility of selecting the wrong product. (2.1)
- Tracheal intubation: Recommended initial dose is 0.6 mg/kg. (2.2)
- Rapid sequence intubation: 0.6 mg/kg to 1.2 mg/kg. (2.3)
- Maintenance doses: Guided by response to prior dose, not administered until recovery is evident. (2.4)
- Continuous infusion: Initial rate of 10 mcg/kg/min to 12 mcg/kg/min. Start only after early evidence of spontaneous recovery from an intubating dose. (2.5)
2.1 Important Dosing and Administration Information
2.1 Important Dosing and Administration Information Rocuronium Bromide Injection is for intravenous use only. Rocuronium Bromide Injection should only be administered by experienced clinicians or trained individuals supervised by an experienced clinician familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents.
Doses of Rocuronium Bromide Injection should be individualized and a peripheral nerve stimulator should be used to monitor drug effect, need for additional doses, adequacy of spontaneous recovery or antagonism, and to decrease the complications of overdosage if additional doses are administered. The dosage information which follows is derived from studies based upon units of drug per unit of body weight.
It is intended to serve as an initial guide to clinicians familiar with other neuromuscular blocking agents to acquire experience with Rocuronium Bromide Injection. In patients in whom potentiation of, or resistance to, neuromuscular block is anticipated, a dose adjustment should be considered [see Dosage and Administration (2.6), Warnings and Precautions (5.10, 5.13), Drug Interactions (7.2, 7.3, 7.4, 7.5, 7.6, 7.8, 7.10), Use in Specific Populations (8.6)].
Risk of Medication Errors Accidental administration of neuromuscular blocking agents may be fatal. Store Rocuronium Bromide Injection Single-Dose Vials with the tamper evidence cap and ferrule intact, and store Rocuronium Bromide Injection Single-Dose Prefilled Syringe with the tamper evidence cap intact. Store Rocuronium Bromide Injection in a manner that minimizes the possibility of selecting the wrong product [see Warnings and Precautions (5.3)].
2.2 Dose for Tracheal Intubation
2.2 Dose for Tracheal Intubation The recommended initial dose of Rocuronium Bromide Injection, regardless of anesthetic technique, is 0.6 mg/kg. Neuromuscular block sufficient for intubation (80% block or greater) is attained in a median (range) time of 1 (0.4-6) minute(s) and most patients have intubation completed within 2 minutes.
Maximum blockade is achieved in most patients in less than 3 minutes. This dose may be expected to provide 31 (15-85) minutes of clinical relaxation under opioid/nitrous oxide/oxygen anesthesia. Under halothane, isoflurane, and enflurane anesthesia, some extension of the period of clinical relaxation should be expected [see Drug Interactions (7.3)].
A lower dose of Rocuronium Bromide Injection (0.45 mg/kg) may be used. Neuromuscular block sufficient for intubation (80% block or greater) is attained in a median (range) time of 1.3 (0.8-6.2) minute(s), and most patients have intubation completed within 2 minutes. Maximum blockade is achieved in most patients in less than 4 minutes.
This dose may be expected to provide 22 (12-31) minutes of clinical relaxation under opioid/nitrous oxide/oxygen anesthesia. Patients receiving this low dose of 0.45 mg/kg who achieve less than 90% block (about 16% of these patients) may have a more rapid time to 25% recovery, 12 to 15 minutes. A large bolus dose of 0.9 mg/kg or 1.2 mg/kg can be administered under opioid/nitrous oxide/oxygen anesthesia without adverse effects to the cardiovascular system [see Clinical Pharmacology (12.2)].
2.3 Rapid Sequence Intubation
2.3 Rapid Sequence Intubation In appropriately premedicated and adequately anesthetized patients, Rocuronium Bromide Injection 0.6 mg/kg to 1.2 mg/kg will provide excellent or good intubating conditions in most patients in less than 2 minutes [see Clinical Studies (14.1)].
2.4 Maintenance Dosing
2.4 Maintenance Dosing Maintenance doses of 0.1 mg/kg, 0.15 mg/kg, and 0.2 mg/kg Rocuronium Bromide Injection, administered at 25% recovery of control T 1 (defined as 3 twitches of train-of-four), provide a median (range) of 12 (2-31), 17 (6-50), and 24 (7-69) minutes of clinical duration under opioid/nitrous oxide/oxygen anesthesia [see Clinical Pharmacology (12.2)]. In all cases, dosing should be guided based on the clinical duration following initial dose or prior maintenance dose and not administered until recovery of neuromuscular function is evident.
A clinically insignificant cumulation of effect with repetitive maintenance dosing has been observed [see Clinical Pharmacology (12.2)].
2.5 Use by Continuous Infusion
2.5 Use by Continuous Infusion Infusion at an initial rate of 10 mcg/kg/min to 12 mcg/kg/min of Rocuronium Bromide Injection should be initiated only after early evidence of spontaneous recovery from an intubating dose. Due to rapid redistribution [see Clinical Pharmacology (12.3)] and the associated rapid spontaneous recovery, initiation of the infusion after substantial return of neuromuscular function (more than 10% of control T 1) may necessitate additional bolus doses to maintain adequate block for surgery.
Upon reaching the desired level of neuromuscular block, the infusion of Rocuronium Bromide Injection must be individualized for each patient. The rate of administration should be adjusted according to the patient's twitch response as monitored with the use of a peripheral nerve stimulator. In clinical trials, infusion rates have ranged from 4 mcg/kg/min to 16 mcg/kg/min.
Inhalation anesthetics, particularly enflurane and isoflurane, may enhance the neuromuscular blocking action of nondepolarizing muscle relaxants. In the presence of steady-state concentrations of enflurane or isoflurane, it may be necessary to reduce the rate of infusion by 30% to 50%, at 45 to 60 minutes after the intubating dose.
Spontaneous recovery and reversal of neuromuscular blockade following discontinuation of Rocuronium Bromide Injection infusion may be expected to proceed at rates comparable to that following comparable total doses administered by repetitive bolus injections [see Clinical Pharmacology (12.2)]. Dilution Infusion solutions of Rocuronium Bromide Injection can be prepared to concentrations of 0.5 mg/mL to 5 mg/mL by mixing Rocuronium Bromide Injection with an appropriate infusion solution such as 5% glucose in water or lactated Ringers [see Dosage and Administration (2.7)].
Use the infusion solutions within 24 hours of mixing. Discard unused portions of infusion solutions. Infusion rates of Rocuronium Bromide Injection can be individualized for each patient using the following tables for 3 different concentrations of Rocuronium Bromide Injection solution as guidelines: Table 1: Infusion Rates Using Rocuronium Bromide Injection (0.5 mg/ mL)* * 50 mg Rocuronium Bromide Injection in 100 mL solution.
Patient Weight Drug Delivery Rate (mcg/kg/min) (kg) 4 5 6 7 8 9 10 12 14 16 Infusion Delivery Rate (mL/hr) 10 4.8 6 7.2 8.4 9.6 10.8 12 14.4 16.8 19.2 15 7.2 9 10.8 12.6 14.4 16.2 18 21.6 25.2 28.8 20 9.6 12 14.4 16.8 19.2 21.6 24 28.8 33.6 38.4 25 12 15 18 21 24 27 30 36 42 48 35 16.8 21 25.2 29.4 33.6 37.8 42 50.4 58.8 67.2 50 24 30 36 42 48 54 60 72 84 96 60 28.8 36 43.2 50.4 57.6 64.8 72 86.4 100.8 115.2 70 33.6 42 50.4 58.8 67.2 75.6 84 100.8 117.6 134.4 80 38.4 48 57.6 67.2 76.8 86.4 96 115.2 134.4 153.6 90 43.2 54 64.8 75.6 86.4 97.2 108 129.6 151.2 172.8 100 48 60 72 84 96 108 120 144 168 192 Table 2: Infusion Rates Using Rocuronium Bromide Injection (1 mg/ mL)* * 100 mg Rocuronium Bromide Injection in 100 mL solution. Patient Weight Drug Delivery Rate (mcg/kg/min) (kg) 4 5 6 7 8 9 10 12 14 16 Infusion Delivery Rate (mL/hr) 10 2.4 3 3.6 4.2 4.8 5.4 6 7.2 8.4 9.6 15 3.6 4.5 5.4 6.3 7.2 8.1 9 10.8 12.6 14.4 20 4.8 6 7.2 8.4 9.6 10.8 12 14.4 16.8 19.2 25 6 7.5 9 10.5 12 13.5 15 18 21 24 35 8.4 10.5 12.6 14.7 16.8 18.9 21 25.2 29.4 33.6 50 12 15 18 21 24 27 30 36 42 48 60 14.4 18 21.6 25.2 28.8 32.4 36 43.2 50.4 57.6 70 16.8 21 25.2 29.4 33.6 37.8 42 50.4 58.8 67.2 80 19.2 24 28.8 33.6 38.4 43.2 48 57.6 67.2 76.8 90 21.6 27 32.4 37.8 43.2 48.6 54 64.8 75.6 86.4 100 24 30 36 42 48 54 60 72 84 96 Table 3: Infusion Rates Using Rocuronium Bromide Injection (5 mg/ mL)* * 500 mg Rocuronium Bromide Injection in 100 mL solution.
Patient Weight Drug Delivery Rate (mcg/kg/min) (kg) 4 5 6 7 8 9 10 12 14 16 Infusion Delivery Rate (mL/hr) 10 0.5 0.6 0.7 0.8 1 1.1 1.2 1.4 1.7 1.9 15 0.7 0.9 1.1 1.3 1.4 1.6 1 8 2.2 2.5 2.9 20 1 1.2 1.4 1.7 1.9 2.2 2.4 2.9 3.4 3.8 25 1.2 1.5 1.8 2.1 2.4 2.7 3 3.6 4.2 4.8 35 1.7 2.1 2.5 2.9 3.4 3.8 4.2 5 5.9 6.7 50 2.4 3 3.6 4.2 4.8 5.4 6 7.2 8.4 9.6 60 2.9 3.6 4.3 5 5.8 6.5 7.2 8.6 10.1 11.5 70 3.4 4.2 5 5.9 6.7 7.6 8.4 10.1 11.8 13.4 80 3.8 4.8 5.8 6.7 7.7 8.6 9.6 11.5 13.4 15.4 90 4.3 5.4 6.5 7.6 8.6 9.7 10.8 13 15.1 17.3 100 4.8 6 7.2 8.4 9.6 10.8 12 14.4 16.8 19.2
2.6 Dosage in Specific Populations Pediatric Patients
2.6 Dosage in Specific Populations Pediatric Patients The recommended initial intubation dose of Rocuronium Bromide Injection is 0.6 mg/kg; however, a lower dose of 0.45 mg/kg may be used depending on anesthetic technique and the age of the patient. For sevoflurane (induction) Rocuronium Bromide Injection doses of 0.45 mg/kg and 0.6 mg/kg in general produce excellent to good intubating conditions within 75 seconds.
When halothane is used, a 0.6 mg/kg dose of Rocuronium Bromide Injection resulted in excellent to good intubating conditions within 60 seconds. The time to maximum block for an intubating dose was shortest in infants (28 days up to 3 months) and longest in neonates (birth to less than 28 days). The duration of clinical relaxation following an intubating dose is shortest in children (greater than 2 years up to 11 years) and longest in infants.
When sevoflurane is used for induction and isoflurane/nitrous oxide for maintenance of general anesthesia, maintenance dosing of Rocuronium Bromide Injection can be administered as bolus doses of 0.15 mg/kg at reappearance of T 3 in all pediatric age groups. Maintenance dosing can also be administered at the reappearance of T 2 at a rate of 7 mcg/kg/min to 10 mcg/kg/min, with the lowest dose requirement for neonates (birth to less than 28 days) and the highest dose requirement for children (greater than 2 years up to 11 years).
When halothane is used for general anesthesia, patients ranging from 3 months old through adolescence can be administered Rocuronium Bromide Injection maintenance doses of 0.075 mg/kg to 0.125 mg/kg upon return of T 1 to 0.25% to provide clinical relaxation for 7 to 10 minutes. Alternatively, a continuous infusion of Rocuronium Bromide Injection initiated at a rate of 12 mcg/kg/min upon return of T 1 to 10% (one twitch present in train-of-four) may also be used to maintain neuromuscular blockade in pediatric patients.
Additional information for administration to pediatric patients of all age groups is presented elsewhere in the label [see Clinical Pharmacology (12.2)]. The infusion of Rocuronium Bromide Injection must be individualized for each patient. The rate of administration should be adjusted according to the patient's twitch response as monitored with the use of a peripheral nerve stimulator.
Spontaneous recovery and reversal of neuromuscular blockade following discontinuation of Rocuronium Bromide Injection infusion may be expected to proceed at rates comparable to that following similar total exposure to single bolus doses [see Clinical Pharmacology (12.2)]. Rocuronium Bromide Injection is not recommended for rapid sequence intubation in pediatric patients.
Geriatric Patients Geriatric patients (65 years or older) exhibited a slightly prolonged median (range) clinical duration of 46 (22-73), 62 (49-75), and 94 (64-138) minutes under opioid/nitrous oxide/oxygen anesthesia following doses of 0.6 mg/kg, 0.9 mg/kg, and 1.2 mg/kg, respectively. No differences in duration of neuromuscular blockade following maintenance doses of Rocuronium Bromide Injection were observed between these subjects and younger subjects, but greater sensitivity of some older individuals cannot be ruled out [see Warnings and Precautions (5.5), Clinical Pharmacology (12.2), Clinical Studies (14.2)].
Patients with Renal or Hepatic Impairment No differences from patients with normal hepatic and kidney function were observed for onset time at a dose of 0.6 mg/kg Rocuronium Bromide Injection. When compared to patients with normal renal and hepatic function, the mean clinical duration is similar in patients with end-stage renal disease undergoing renal transplant and is about 1.5 times longer in patients with hepatic disease.
Patients with renal failure may have a greater variation in duration of effect [see Use in Specific Populations (8.6, 8.7), Clinical Pharmacology (12.3)]. Obese Patients In obese patients, the initial dose of Rocuronium Bromide Injection 0.6 mg/kg should be based upon the patient's actual body weight [see Clinical Studies (14.1)].
An analysis across all US controlled clinical studies indicates that the pharmacodynamics of Rocuronium Bromide Injection are not different between obese and nonobese patients when dosed based upon their actual body weight. Patients with Reduced Plasma Cholinesterase Activity Rocuronium metabolism does not depend on plasma cholinesterase so dosing adjustments are not needed in patients with reduced plasma cholinesterase activity.
Patients with Prolonged Circulation Time Because higher doses of Rocuronium Bromide Injection produce a longer duration of action, the initial dosage should usually not be increased in these patients to reduce onset time; instead, in these situations, when feasible, more time should be allowed for the drug to achieve onset of effect [see Warnings and Precautions (5.8)]. Patients with Drugs or Conditions Causing Potentiation of Neuromuscular Block The neuromuscular blocking action of Rocuronium Bromide Injection is potentiated by isoflurane and enflurane anesthesia.
Potentiation is minimal when administration of the recommended dose of Rocuronium Bromide Injection occurs prior to the administration of these potent inhalation agents. The median clinical duration of a dose of 0.57 mg/kg to 0.85 mg/kg was 34, 38, and 42 minutes under opioid/nitrous oxide/oxygen, enflurane and isoflurane maintenance anesthesia, respectively.
During 1 to 2 hours of infusion, the infusion rate of Rocuronium Bromide Injection required to maintain about 95% block was decreased by as much as 40% under enflurane and isoflurane anesthesia [see Drug Interactions (7.3)].
2.7 Drug Compatibilities for Rocuronium Bromide Injection Diluent
2.7 Drug Compatibilities for Rocuronium Bromide Injection Diluent Compatibility Rocuronium Bromide Injection is compatible in solution with: 0.9% NaCl solution sterile water for injection 5% glucose in water lactated Ringers 5% glucose in saline Rocuronium Bromide Injection is compatible in the above solutions at concentrations up to 5 mg/mL for 24 hours at room temperature in plastic bags, glass bottles, and plastic syringe pumps. Drug Admixture Incompatibility Rocuronium Bromide Injection is physically incompatible when mixed with the following drugs: amphotericin hydrocortisone sodium succinate amoxicillin insulin azathioprine Intralipid cefazolin ketorolac cloxacillin lorazepam dexamethasone methohexital diazepam methylprednisolone erythromycin thiopental famotidine trimethoprim furosemide vancomycin If Rocuronium Bromide Injection is administered via the same infusion line that is also used for other drugs, it is important that this infusion line is adequately flushed between administration of Rocuronium Bromide Injection and drugs for which incompatibility with Rocuronium Bromide Injection has been demonstrated or for which compatibility with Rocuronium Bromide Injection has not been established.
Infusion solutions should be used within 24 hours of mixing. Unused portions of infusion solutions should be discarded. Rocuronium Bromide Injection should not be mixed with alkaline solutions [see Warnings and Precautions (5.11)]. Visual Inspection Parenteral drug products should be inspected visually for particulate matter and clarity prior to administration whenever solution and container permit.
Do not use solution if particulate matter is present.
Dosing: Altered kidney function
8.7 Patients with Renal Impairment Due to the limited role of the kidney in the excretion of rocuronium bromide, usual dosing recommendations Rocuronium Bromide Injection for should be followed. In patients with renal dysfunction, the duration of neuromuscular blockade was not prolonged; however, there was substantial individual variability (range: 22 to 90 minutes) [see Clinical Pharmacology (12.3)].
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.6 Patients with Hepatic Impairment Because rocuronium bromide is primarily excreted by the liver, it should be used with caution in patients with clinically significant hepatic impairment. Another rocuronium bromide injection product (0.6 mg/kg) was studied in a limited number of patients (n=9) with clinically significant hepatic impairment under steady-state isoflurane anesthesia.
After rocuronium bromide injection administration (0.6 mg/kg), the median (range) clinical duration of 60 (35-166) minutes was moderately prolonged compared to 42 minutes in patients with normal hepatic function. The median recovery time of 53 minutes was also prolonged in patients with cirrhosis compared to 20 minutes in patients with normal hepatic function.
Four of 8 patients with cirrhosis, who received the other rocuronium bromide injection product (0.6 mg/kg) under opioid/nitrous oxide/oxygen anesthesia, did not achieve complete block. These findings are consistent with the increase in volume of distribution at steady state observed in patients with significant hepatic impairment [see Clinical Pharmacology (12.3)].
If used for rapid sequence induction in patients with ascites, an increased initial dosage of Rocuronium Bromide Injection may be necessary to assure complete block. Duration will be prolonged in these cases. The use of Rocuronium Bromide Injection doses higher than 0.6 mg/kg has not been studied [see Dosage and Administration (2.6)].
US FDA labelAdministration
2.1 Important Dosing and Administration Information Rocuronium Bromide Injection is for intravenous use only. Rocuronium Bromide Injection should only be administered by experienced clinicians or trained individuals supervised by an experienced clinician familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents. Doses of Rocuronium Bromide Injection should be individualized and a peripheral nerve stimulator should be used to monitor drug effect, need for additional doses, adequacy of spontaneous recovery or antagonism, and to decrease the complications of overdosage if additional doses are administered. The dosage information which follows is derived from studies based upon units of drug per unit of body weight. It is intended to serve as an initial guide to clinicians familiar with other neuromuscular blocking agents to acquire experience with Rocuronium Bromide Injection. In patients in whom potentiation of, or resistance to, neuromuscular block is anticipated, a dose adjustment should be considered [see Dosage and Administration ( 2.6 ), Warnings and Precautions ( 5.10 , 5.13 ), Drug Interactions ( 7.2 , 7.3 , 7.4 , 7.5 , 7.6 , 7.8 , 7.10 ), Use in Specific Populations ( 8.6 )] . Risk of Medication Errors Accidental administration of neuromuscular blocking agents may be fatal. Store Rocuronium Bromide Injection Single-Dose Vials with the tamper evidence cap and ferrule intact, and store Rocuronium Bromide Injection Single-Dose Prefilled Syringe with the tamper evidence cap intact. Store Rocuronium Bromide Injection in a manner that minimizes the possibility of selecting the wrong product [see Warnings and Precautions ( 5.3 )] .
2.5 Use by Continuous Infusion Infusion at an initial rate of 10 mcg/kg/min to 12 mcg/kg/min of Rocuronium Bromide Injection should be initiated only after early evidence of spontaneous recovery from an intubating dose. Due to rapid redistribution [see Clinical Pharmacology ( 12.3 )] and the associated rapid spontaneous recovery, initiation of the infusion after substantial return of neuromuscular function (more than 10% of control T 1 ) may necessitate additional bolus doses to maintain adequate block for surgery. Upon reaching the desired level of neuromuscular block, the infusion of Rocuronium Bromide Injection must be individualized for each patient. The rate of administration should be adjusted according to the patient's twitch response as monitored with the use of a peripheral nerve stimulator. In clinical trials, infusion rates have ranged from 4 mcg/kg/min to 16 mcg/kg/min. Inhalation anesthetics, particularly enflurane and isoflurane, may enhance the neuromuscular blocking action of nondepolarizing muscle relaxants. In the presence of steady-state concentrations of enflurane or isoflurane, it may be necessary to reduce the rate of infusion by 30% to 50%, at 45 to 60 minutes after the intubating dose. Spontaneous recovery and reversal of neuromuscular blockade following discontinuation of Rocuronium Bromide Injection infusion may be expected to proceed at rates comparable to that following comparable total doses administered by repetitive bolus injections [see Clinical Pharmacology ( 12.2 )]. Dilution Infusion solutions of Rocuronium Bromide Injection can be prepared to concentrations of 0.5 mg/mL to 5 mg/mL by mixing Rocuronium Bromide Injection with an appropriate infusion solution such as 5% glucose in water or lactated Ringers [see Dosage and Administration ( 2.7 )]. Use the infusion solutions within 24 hours of mixing. Discard unused portions of infusion solutions. Infusion rates of Rocuronium Bromide Injection can be individualized for each patient using the following tables for 3 different concentrations of Rocuronium Bromide Injection solution as guidelines: Table 1: Infusion Rates Using Rocuronium Bromide Injection (0.5 mg/ mL)* * 50 mg Rocuronium Bromide Injection in 100 mL solution. Patient Weight Drug Delivery Rate (mcg/kg/min) (kg) 4 5 6 7 8 9 10 12 14 16 Infusion Delivery Rate (mL/hr) 10 4.8 6 7.2 8.4 9.6 10.8 12 14.4 16.8 19.2 15 7.2 9 10.8 12.6 14.4 16.2 18 21.6 25.2 28.8 20 9.6 12 14.4 16.8 19.2 21.6 24 28.8 33.6 38.4 25 12 15 18 21 24 27 30 36 42 48 35 16.8 21 25.2 29.4 33.6 37.8 42 50.4 58.8 67.2 50 24 30 36 42 48 54 60 72 84 96 60 28.8 36 43.2 50.4 57.6 64.8 72 86.4 100.8 115.2 70 33.6 42 50.4 58.8 67.2 75.6 84 100.8 117.6 134.4 80 38.4 48 57.6 67.2 76.8 86.4 96 115.2 134.4 153.6 90 43.2 54 64.8 75.6 86.4 97.2 108 129.6 151.2 172.8 100 48 60 72 84 96 108 120 144 168 192 Table 2: Infusion Rates Using Rocuronium Bromide Injection (1 mg/ mL)* * 100 mg Rocuronium Bromide Injection in 100 mL solution. Patient Weight Drug Delivery Rate (mcg/kg/min) (kg) 4 5 6 7 8 9 10 12 14 16 Infusion Delivery Rate (mL/hr) 10 2.4 3 3.6 4.2 4.8 5.4 6 7.2 8.4 9.6 15 3.6 4.5 5.4 6.3 7.2 8.1 9 10.8 12.6 14.4 20 4.8 6 7.2 8.4 9.6 10.8 12 14.4 16.8 19.2 25 6 7.5 9 10.5 12 13.5 15 18 21 24 35 8.4 10.5 12.6 14.7 16.8 18.9 21 25.2 29.4 33.6 50 12 15 18 21 24 27 30 36 42 48 60 14.4 18 21.6 25.2 28.8 32.4 36 43.2 50.4 57.6 70 16.8 21 25.2 29.4 33.6 37.8 42 50.4 58.8 67.2 80 19.2 24 28.8 33.6 38.4 43.2 48 57.6 67.2 76.8 90 21.6 27 32.4 37.8 43.2 48.6 54 64.8 75.6 86.4 100 24 30 36 42 48 54 60 72 84 96 Table 3: Infusion Rates Using Rocuronium Bromide Injection (5 mg/ mL)* * 500 mg Rocuronium Bromide Injection in 100 mL solution. Patient Weight Drug Delivery Rate (mcg/kg/min) (kg) 4 5 6 7 8 9 10 12 14 16 Infusion Delivery Rate (mL/hr) 10 0.5 0.6 0.7 0.8 1 1.1 1.2 1.4 1.7 1.9 15 0.7 0.9 1.1 1.3 1.4 1.6 1 8 2.2 2.5 2.9 20 1 1.2 1.4 1.7 1.9 2.2 2.4 2.9 3.4 3.8 25 1.2 1.5 1.8 2.1 2.4 2.7 3 3.6 4.2 4.8 35 1.7 2.1 2.5 2.9 3.4 3.8 4.2 5 5.9 6.7 50 2.4 3 3.6 4.2 4.8 5.4 6 7.2 8.4 9.6 60 2.9 3.6 4.3 5 5.8 6.5 7.2 8.6 10.1 11.5 70 3.4 4.2 5 5.9 6.7 7.6 8.4 10.1 11.8 13.4 80 3.8 4.8 5.8 6.7 7.7 8.6 9.6 11.5 13.4 15.4 90 4.3 5.4 6.5 7.6 8.6 9.7 10.8 13 15.1 17.3 100 4.8 6 7.2 8.4 9.6 10.8 12 14.4 16.8 19.2
2.7 Drug Compatibilities for Rocuronium Bromide Injection Diluent Compatibility Rocuronium Bromide Injection is compatible in solution with: 0.9% NaCl solution sterile water for injection 5% glucose in water lactated Ringers 5% glucose in saline Rocuronium Bromide Injection is compatible in the above solutions at concentrations up to 5 mg/mL for 24 hours at room temperature in plastic bags, glass bottles, and plastic syringe pumps. Drug Admixture Incompatibility Rocuronium Bromide Injection is physically incompatible when mixed with the following drugs: amphotericin hydrocortisone sodium succinate amoxicillin insulin azathioprine Intralipid cefazolin ketorolac cloxacillin lorazepam dexamethasone methohexital diazepam methylprednisolone erythromycin thiopental famotidine trimethoprim furosemide vancomycin If Rocuronium Bromide Injection is administered via the same infusion line that is also used for other drugs, it is important that this infusion line is adequately flushed between administration of Rocuronium Bromide Injection and drugs for which incompatibility with Rocuronium Bromide Injection has been demonstrated or for which compatibility with Rocuronium Bromide Injection has not been established. Infusion solutions should be used within 24 hours of mixing. Unused portions of infusion solutions should be discarded. Rocuronium Bromide Injection should not be mixed with alkaline solutions [see Warnings and Precautions ( 5.11 )] . Visual Inspection Parenteral drug products should be inspected visually for particulate matter and clarity prior to administration whenever solution and container permit. Do not use solution if particulate matter is present.
US FDA labelDosage forms
Philippines
- Solution for injection: 10 mg/mL
- ) solution for injection: 10 mg/mL (100 mg/10 mL, 10 mg/mL (50 mg/5 mL, 100 mg/mL (100 mg/10 mL
- ) solution for i.v. for injection: 50 mg/5 mL (10 mg/mL
- ) solution for injection/ infusion: 50 mg/5 mL (10 mg/mL
- ) solution for iv injection/infusion: 10 mg/mL (50 mg/5 mL
Registered products in the Philippines
34 products registered with the Food and Drug Administration (FDA) Philippines list Rocuronium as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products34
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AmbrocorRocuronium Bromide | 50 mg/5 mL (10 mg/mL) Solution for Injection/ InfusionNeutral Borosilicate Glass Ampoules x 5 mL (Box of 5's) | Rx | Guangdong Jiabo Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-16950 | Aug 29, 2030 | |
BromkelRocuronium bromide | 10 mg/mL Solution for Injection (IV)USP Type I Glass Vial with grey colored chlorobutyl rubber stopper and orange colored aluminum flip-Off Cap x 5 mL (Box of 10 vials x 5 mL) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Ellebasy Medicale Group Inc.Importer: JLT Pharma, Inc. | DRP-13219-01 | Jan 3, 2028 | |
CurocentRocuronium Bromide | 10 mg/mL Solution for Injection (IV)USP Type I Glass Vial with grey colored chlorobutyl rubber stopper and orange colored aluminum flip-Off Cap x 5 mL (Box of 10 vials x 5mL) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Central West Medicale Inc.Importer: JLT Pharma Inc. | DRP-13219-03 | Jan 3, 2028 | |
DexmeronRocuronium Bromide | 10 mg/mL (50 mg/5 mL) Solution For Injection (IV)5mL Clear Glass Vial with Grey Bromobutyl Rubber Stopper and Alu/Polypropylene Flip-off Seal (Box of 10's) | Rx | Concept Pharmaceuticals Ltd.India | Medethix, Inc. | DRP-18615 | Aug 5, 2031 | |
EsmeronRocuronium Bromide | 50 mg/5 mL (10 mg/mL) Solution for I.V. for InjectionGlass Vial x 5 mL Box of 10's | Rx | N.V. OrganonNetherlands | Importer: MERCK SHARP & DOHME (I.A.) LLC | DRP-6246 | Dec 16, 2029 | |
FironiumRocuronium Bromide | 10 mg/mL Solution for Injection (IV)Flint glass vial x 5 mL with rubber stopper and blue aluminium flip-off seal (Box of l’s) | Rx | PT. BernofarmIndonesia | Dreamax Incorporated | DRP-11916 | May 30, 2027 | |
GinhawaGet-100Rocuronium Bromide | 100 mg/mL (100 mg/10 mL) Solution For Injection (IV)Usp Type I Flint Molded Glass Vial With Grey Bromobutyl Slotted RFU Rubber Stopper And Ice Blue-Colored Aluminum Flip-off Seal x 10 mL (Box of 1's) | Rx | Stanex Drugs & Chemicals Pvt. Ltd.India | 2MG Incorporated | DRP-18379 | Jun 24, 2031 | |
GocuroniumRocuronium Bromide | 10 mg / mL Solution for Injection (IV)USP Type I clear glass vial grey bromobutyl rubber stopper, aluminum seal and light-blue flip-off cap x 5 ml and 10 mL (Box of 1’s and 10's) | Rx | Kilitch Drugs (India) Ltd.India | Applied Pharmaceutical Distribution Inc.Importer: Ollen Pharma Trading Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-12979-01 | Nov 11, 2027 | |
KabirocRocuronium Bromide | 10 mg/mL (50mg/5mL) Solution for IV Injection/InfusionType I Clear and Colorless Glass Vial (Box of 10's) | Rx | Fresenius Kabi Austria GmbhAustria | Fresenius Kabi Philippines, Inc. | DR-XY44618 | Jun 4, 2031 | |
KabirocRocuronium Bromide | 10 mg/mL Solution For Injection (IV)Type I Clear Glass Ampoule x 5 mL (Box of 5's) | Rx | PT. Ethica Industri FarmasiIndonesia | Importer: Fresenius Kabi Philippines, Inc. | DR-XY48637 | Feb 23, 2028 | |
KabirocRocuronium Bromide | 10 mg/mL Solution for Injection (IV)Type I clear glass vial x 5 mL with grey bromobutyl rubber stopper, alumimum seal and blue flip-off cap seal with (Box of 10's) | Rx | Fresenius Kabi Austria GmbHAustria | Fresenius Kabi Philippines, Inc. | DR-XY49319 | Jan 28, 2030 | |
MedcuromRocuronium bromide | 10 mg/mL (50 mg/5 mL) Solution for Injection (I.V.)5 mL-capacity USP Type I Clear and Colorless Glass Vial with Grey Chlorobutyl Rubber Stopper and Red colored Aluminum Seal with Yellow-colored Flip-Off Cap (Box of 10's) | Rx | Maiva Pharma Private LimitedIndia | Vivilon Pharmaceuticals Inc.Importer: Medethix, Inc.Trader: I-Care Formulations | DRP-9359-01 | Jun 23, 2031 | |
MuscoronRocuronium bromide | 10 mg/mL (50 mg/5 mL) Solution for Injection (I.V.)5 mL-capacity USP Type I Clear and Colorless Glass Vial with Grey Chlorobutyl Rubber Stopper and Red colored Aluminum Seal with Yellow-colored Flip-Off (Box of 10's) | Rx | Maiva Pharma Private LimitedIndia | Buehler Pharma and Medical Trading Corp.Importer: Medethix, Inc.Trader: I- Care Formulations | DRP-9359 | Dec 4, 2031 | |
NeumeronRocuronium Bromide | 10 mg/mL Solution for Injection (IV)USP Type I Clear Glass Vial x 5 mL with bromobutyl Rubber Stopper and Sealed with Flip-off Aluminum Seal (Box of 12's) | Rx | Gland Pharma LimitedIndia | Endure Medical, Inc. | DR-XY42370 | Aug 12, 2028 | |
NoveronRocuronium Bromide | 10 mg/mL Solution for Injection (IV)Type I Clear Glass Vial with Grey Bromobutyl Rubber Stopper and Yellow Flip-off Seal x 5 mL (Box of 12's) | Rx | PT. Novell Pharmaceutical LaboratoriesBogor 16962 - Indonesia | Prosweal Healthcare Inc. | DRP-7078 | Mar 7, 2032 | |
ReposeRocuronium Bromide | 10 mg/mL Solution for Injection (IV)In 5 mL USP Type I Clear Glass Vial with Dark Grey Bromobutyl Rubber Stopper and Yellow Flip-Off Seal (Box of 10's) | Rx | Gland Pharma LimitedIndia | Biocare Lifesciences, Inc. | DRP-8944 | Jul 6, 2030 | |
RocniumRocuronium Bromide | 10 mg/mL (50mg/5mL) Solution for Injection (IV)Type I Clear and colorless glass vial with chlorobutyl rubber stopper and aluminum cap x 5 mL (Box of 10's) | Rx | Hanlim Pharm. Co., Ltd.Korea | Endure Medical, Inc | DR-XY49517 | Sep 15, 2030 | |
RocuGetRocuronium Bromide | 10 mg/mL Solution for Injection (IV)Type I Clear glass vial with gray chlorobutyl rubber stopper and orange flip off aluminum seal x 5 mL (Box of 1's); Type I Clear glass vial with gray chlorobutyl rubber stopper and sky blue flip off aluminum seal x 10 mL Box of 1's | Rx | Aspiro Pharma LimitedIndia | Getmeds Philippines Inc.Importer: Camber Pharmaceuticals, Inc. | DRP-11299-01 | Nov 24, 2026 | |
RocuGet-100Rocuronium bromide | 10 mg/mL (100mg/10mL) Solution for Injection (IV)USP Type I flint molded glass vial with grey bromobutyl RFU rubber stopper and ice blue-colored aluminum flip-off seal x 10mL (Box of 1's) | Rx | Stanex Drugs & Chemicals Pvt. Ltd.India | GetMeds Philippines Inc.Importer: 2MG Incorporated | DRP-18379-01 | Jul 22, 2031 | |
RocumRocuronium Bromide | 10 mg/mL Solution For Injection (IV)USP Type I Clear Glass Ampoule x 5 mL (Box of 10's) | Rx | PT Ferron PAR PharmaceuticalsIndonesia | Glorious Dexa Mandaya, Inc.Trader: PT Dexa Medica | DR-XY47769 | Mar 4, 2027 | |
RocumedRocuronium bromide | 10 mg/mL (50 mg/5 mL) Solution for Injection (IV)5 mL capacity USP Type I Clear and Colorless Glass vial with Grey Chlorobutyl Rubber Stopper and Red colored Aluminum seal with yellow colored flip-off cap (Box of 10's) | Rx | Maiva Pharma Private LimitedIndia | Delex Pharma International, Inc.Importer: Medethix, Inc.Trader: I-Care Formulations | DRP-9359-02 | Jul 20, 2031 | |
RocunovaRocuronium Bromide | 10 mg/mL Solution for Injection (IV)USP Type I Clear Glass Tubular vials with gray colored bromobutyl rubber stopper and green colored aluminum flip-off seal x 5 mL (Box of 1's) | Rx | Immacule Lifesciences Private LimitedIndia | Medinova Pharmaceutical Inc. | DRP-10626 | Nov 26, 2026 | |
RocurinRocuronium bromide | 10mg/mL (50mg/5mL) Solution for Injection (IV)Type I Clear Flint Tubular Glass Vial Sealed with Bromobutyl Rubber Stopper and Aluminum Seal with Green Flip-Off Cap x 5mL in Plastic Tray (Box of 1's) | Rx | Indasi Lifescience Pvt. Ltd.India | Aglobal Care, Inc. | DRP-17397 | Dec 10, 2030 | |
RocuroniusaphRocuronium Bromide | 10mg/mL Solution for Injection (IV)USP Type I clear glass vial grey bromobutyl rubber, stopper, aluminum seal and light-blue flip-off cap x 5 mL and 10 mL (Box of 1's and 10's) | Rx | Kilitch Drugs (India) Ltd.India | Ollen Pharma Trading Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-12979 | Nov 11, 2027 | |
RocurtrisRocuronium Bromide | 10 mg/mL Solution For Injection (Iv)10 mL USP Type I clear glass vial with gray chlorobutyl rubber stopper, and aluminum seal and blue flip off cap (Box of 1's) | Rx | Ratnatris Pharmaceuticals Pvt. Ltd.India | AMB HK Enterprises, Inc. | DRP-18894 | Sep 24, 2032 | |
RocuStarRocuronium Bromide | 10 mg / mL Solution for Injection (IV)USP Type I Glass Vial with grey colored chlorobutyl rubber stopper and orange colored aluminum flip-Off Cap x 5 mL (Box of 10 vials x 5 mL) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Double Lotus Pharm, Inc.Importer: JLT Pharma Inc. | DRP-13219-02 | Jan 3, 2028 | |
RocutamRocuronium bromide | 10 mg / mL (50 mg / 5 mL) Solution for Injection (IV)USP Type I clear and colorless glass vial with grey chlorobutyl rubber stopper and red-colored aluminum seal with yellow-colored flip-off cap x 5 mL (Box of 10's) | Rx | Maiva Pharma Private LimitedIndia | Tamiga Pharmaceuticals SupplyImporter: Medethix, Inc.Trader: I-Care Formulations | DRP-9126-01 | Sep 18, 2028 | |
RocuzenRocuronium bromide. | 10mg/ml Solution for Injection (IV)Type I Glass Vial with grey bromobutyl rubber stopper with flip off seal x 5mL and 10mL (Box of 10's) | Rx | Caplin Steriles LimitedIndia | Despina Pharma Inc. | DRP-15549 | Aug 5, 2029 | |
RomeronRocuronium bromide | 10 mg/mL Solution for Injection (I.V.)USP Type I Glass Vial with grey colored chlorobutyl rubber stopper and orange colored aluminum flip-Off Cap x 5 mL (Box of 10 ampoules x 5 mL) | Rx | BCWorld Pharm. CO., Ltd.Korea | JLT Pharma Inc. | DRP-13219 | Jan 3, 2028 | |
RoneurRocuronium Bromide | 10 mg/mL Solution for Injection (I.V.)USP Type I amber glass vial with grey bromobutyl rubber stopper and aluminum flip-off seal x 5mL (Box of 10's) | Rx | Ciron Drugs & Pharmaceuticals Pvt. Ltd.India | Phil Pharmawealth, Inc.Trader: Oboi Laboratories | DRP-17460 | Sep 30, 2030 | |
RoneurRocuronium bromide | 10 mg/mL Solution for Injection (IV)USP Type I amber glass vial with grey bromobutyl rubber stopper and aluminum flip-off seal x 5 mL (Box of 10's) | Rx | Ciron Drugs & Pharmaceuticals Pvt. LimitedIndia | Phil. Pharmawealth, Inc.Trader: Oboi Laboratories | DR-XY49522 | Sep 30, 2030 | |
Saphcuronium-AltRocuronium Bromide | 10 mg/mL Solution For Injection (I.V.)Type I Clear Glass Ampoule in PVC Tray x 5 mL and 10 mL (Box of 1's and 10's) | Rx | Althea Pharma Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-19023 | Oct 19, 2031 | |
(no brand name)Rocuronium Bromide | 10 mg/mL Solution for Injection (IV)Type I Clear glass vial with gray chlorobutyl rubber stopper and orange flip off aluminum seal x 5 mL (Box of l's); Type I Clear glass vial with gray chlorobutyl rubber stopper and sky blue flip off aluminum seal x 10 mL (Box of l's) | Rx | Aspiro Pharma LimitedIndia | Camber Pharmaceuticals, Inc. | DRP-11299 | Nov 24, 2026 | |
(no brand name)Rocuronium Bromide | 10mg/mL Solution For Injection (IV)Type I Clear and colorless glass vial with chlorobutyl rubber stopper and aluminum cap x 5 mL (Box of 10's) | Rx | Siegfried Hameln GmbHGermany | Enlife Global Inc. | DRP-10869 | Dec 28, 2026 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Rocuronium Bromide Injection is a clear, colorless to yellow/orange solution, free from visible particulate matter available as: 50 mg/5 mL (10 mg/mL), single-dose vials 100 mg/10 mL (10 mg/mL), single-dose vials 50 mg/5 mL (10 mg/mL), single-dose prefilled syringes Injection: 50 mg/5 mL (10 mg/mL), single-dose vial and single-dose prefilled syringe. (3) 100 mg/10 mL (10 mg/mL), single-dose vial. (3)
Warnings/Precautions
- Appropriate Administration and Monitorin g: Use only if facilities for intubation, mechanical ventilation, oxygen therapy, and an antagonist are immediately available. (5.1)
- Anaphylaxis: Severe anaphylaxis has been reported. Consider cross-reactivity among neuromuscular blocking agents. (5.2)
- Risk of Death due to Medication Errors: Accidental administration can cause death. (5.3)
- Need for Adequate Anesthesia: Must be accompanied by adequate anesthesia or sedation. (5.4)
- Residual Paralysis: Consider using a reversal agent in cases where residual paralysis is more likely to occur. (5.5)
5.1 Appropriate Administration and Monitoring
5.1 Appropriate Administration and Monitoring Rocuronium Bromide Injection should be administered in carefully adjusted dosages by or under the supervision of experienced clinicians who are familiar with the drug's actions and the possible complications of its use. Rocuronium Bromide Injection should not be administered unless facilities for intubation, mechanical ventilation, oxygen therapy, and an antagonist are immediately available.
It is recommended that clinicians administering neuromuscular blocking agents such as Rocuronium Bromide Injection employ a peripheral nerve stimulator to monitor drug effect, need for additional doses, adequacy of spontaneous recovery or antagonism, and to decrease the complications of overdosage if additional doses are administered.
5.2 Anaphylaxis
5.2 Anaphylaxis Severe anaphylactic reactions to neuromuscular blocking agents, including Rocuronium Bromide Injection, have been reported. These reactions have, in some cases (including cases with Rocuronium Bromide Injection), been life threatening and fatal. Due to the potential severity of these reactions, the necessary precautions, such as the immediate availability of appropriate emergency treatment, should be taken.
Precautions should also be taken in those patients who have had previous anaphylactic reactions to other neuromuscular blocking agents, since cross-reactivity between neuromuscular blocking agents, both depolarizing and nondepolarizing, has been reported.
5.3 Risk of Death due to Medication Errors Administration of Rocuronium Bromide
5.3 Risk of Death due to Medication Errors Administration of Rocuronium Bromide Injection results in paralysis, which may lead to respiratory arrest and death, a progression that may be more likely to occur in a patient for whom it is not intended. Confirm proper selection of intended product and avoid confusion with other injectable solutions that are present in critical care and other clinical settings.
If another healthcare provider is administering Rocuronium Bromide Injection, ensure that the intended dose is clearly labeled and communicated.
5.4 Need for Adequate Anesthesia
5.4 Need for Adequate Anesthesia Rocuronium Bromide Injection has no known effect on consciousness, pain threshold, or cerebration. Therefore, its administration must be accompanied by adequate anesthesia or sedation.
5.5 Residual Paralysis
5.5 Residual Paralysis To prevent complications resulting from residual paralysis from Rocuronium Bromide Injection, it is recommended to extubate only after the patient has recovered sufficiently from neuromuscular block. Geriatric patients (65 years or older) may be at increased risk for residual neuromuscular block. Other factors which could cause residual paralysis after extubation in the post- operative phase (such as drug interactions or patient condition) should also be considered.
If not used as part of standard clinical practice the use of a reversal agent should be considered, especially in those cases where residual paralysis is more likely to occur.
5.6 Long-Term
5.6 Long-Term Use in an Intensive Care Unit Rocuronium Bromide Injection has not been studied for long-term use in the intensive care unit (ICU). As with other nondepolarizing neuromuscular blocking drugs, apparent tolerance to Rocuronium Bromide Injection may develop during chronic administration in the ICU. While the mechanism for development of this resistance is not known, receptor up-regulation may be a contributing factor.
It is strongly recommended that neuromuscular transmission be monitored continuously during Rocuronium Bromide Injection administration and recovery with the help of a nerve stimulator. Additional doses of Rocuronium Bromide Injection or any other neuromuscular blocking agent should not be given until there is a definite response (one twitch of the train-of-four) to nerve stimulation.
Prolonged paralysis and/or skeletal muscle weakness may be noted during initial attempts to wean from the ventilator patients who have chronically received neuromuscular blocking drugs in the ICU. Myopathy after long-term administration of other nondepolarizing neuromuscular blocking agents in the ICU alone or in combination with corticosteroid therapy has been reported.
Therefore, for patients receiving both neuromuscular blocking agents (including Rocuronium Bromide Injection) and corticosteroids, the period of use of the neuromuscular blocking agent should be limited as much as possible and only used in the setting where in the opinion of the prescribing physician, the specific advantages of the drug outweigh the risk.
5.7 Malignant Hyperthermia
5.7 Malignant Hyperthermia Rocuronium Bromide Injection has not been studied in malignant hyperthermia (MH)-susceptible patients. In an animal study in MH-susceptible swine, the administration of Rocuronium Bromide Injection did not appear to trigger malignant hyperthermia. Because Rocuronium Bromide Injection is always used with other agents, and the occurrence of MH during anesthesia is possible even in the absence of known triggering agents, clinicians should be familiar with early signs, confirmatory diagnosis, and treatment of MH prior to the start of any anesthetic [see Adverse Reactions (6.2)].
5.8 Prolonged Circulation Time
5.8 Prolonged Circulation Time Conditions associated with an increased circulatory delayed time, e.g., cardiovascular disease or advanced age, in patients treated with Rocuronium Bromide Injection may be associated with a delay in onset time [see Dosage and Administration (2.6)].
5.9 QT Interval Prolongation
5.9 QT Interval Prolongation The overall analysis of ECG data in pediatric patients indicates that the concomitant use of Rocuronium Bromide Injection with general anesthetic agents can prolong the QTc interval [see Clinical Studies (14.3)].
5.10 Conditions/Drugs Causing Potentiation
5.10 Conditions/Drugs Causing Potentiation of, or Resistance to, Neuromuscular Block Potentiation Nondepolarizing neuromuscular blocking agents have been found to exhibit profound neuromuscular blocking effects in cachectic or debilitated patients, patients with neuromuscular diseases, and patients with carcinomatosis. Certain inhalation anesthetics, particularly enflurane and isoflurane, antibiotics, magnesium salts, lithium, local anesthetics, procainamide, and quinidine have been shown to increase the duration of neuromuscular block and decrease infusion requirements of neuromuscular blocking agents [see Drug Interactions (7.3)].
In these or other patients in whom potentiation of neuromuscular block or difficulty with reversal may be anticipated, a decrease from the recommended initial dose of Rocuronium Bromide Injection should be considered [see Dosage and Administration (2.6)]. Resistance Resistance to nondepolarizing agents, consistent with up-regulation of skeletal muscle acetylcholine receptors, is associated with burns, disuse atrophy, denervation, and direct muscle trauma.
Receptor up-regulation may also contribute to the resistance to nondepolarizing muscle relaxants which sometimes develops in patients with cerebral palsy, patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, or with chronic exposure to nondepolarizing agents. When Rocuronium Bromide Injection is administered to these patients, shorter durations of neuromuscular block may occur, and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants.
Potentiation or Resistance Severe acid-base and/or electrolyte abnormalities may potentiate or cause resistance to the neuromuscular blocking action of Rocuronium Bromide Injection. No data are available in such patients and no dosing recommendations can be made. Rocuronium Bromide Injection-induced neuromuscular blockade was modified by alkalosis and acidosis in experimental pigs.
Both respiratory and metabolic acidosis prolonged the recovery time. The potency of Rocuronium Bromide Injection was significantly enhanced in metabolic acidosis and alkalosis but was reduced in respiratory alkalosis. In addition, experience with other drugs has suggested that acute (e.g., diarrhea) or chronic (e.g., adrenocortical insufficiency) electrolyte imbalance may alter neuromuscular blockade.
Since electrolyte imbalance and acid-base imbalance are usually mixed, either enhancement or inhibition may occur.
5.11 Incompatibility with Alkaline Solutions
5.11 Incompatibility with Alkaline Solutions Rocuronium Bromide Injection, which has an acid pH, should not be mixed with alkaline solutions (e.g., barbiturate solutions) in the same syringe or administered simultaneously during intravenous infusion through the same needle.
5.12 Increase in Pulmonary Vascular Resistance
5.12 Increase in Pulmonary Vascular Resistance Rocuronium Bromide Injection may be associated with increased pulmonary vascular resistance, so caution is appropriate in patients with pulmonary hypertension or valvular heart disease [see Clinical Studies (14.1)].
5.13 Use in Patients with Myasthenia
5.13 Use in Patients with Myasthenia In patients with myasthenia gravis or myasthenic (Eaton-Lambert) syndrome, small doses of nondepolarizing neuromuscular blocking agents, including Rocuronium Bromide Injection, may have profound effects. In such patients, a peripheral nerve stimulator and use of a small test dose may be of value in monitoring the response to administration of muscle relaxants.
5.14 Extravasation
5.14 Extravasation If extravasation occurs after Rocuronium Bromide Injection administration, it may be associated with signs or symptoms of local irritation. The Rocuronium Bromide Injection or infusion should be terminated immediately and restarted in another vein.
Drug interactions
- Succinylcholine: Use before succinylcholine has not been studied. (7.11)
- Nondepolarizing muscle relaxants: Interactions have been observed. (7.7)
- Enhanced Rocuronium Bromide Injection activity possible: Inhalation anesthetics (7.3), certain antibiotics (7.1), quinidine (7.10), magnesium (7.6), lithium (7.4), local anesthetics (7.5), procainamide (7.8)
- Reduced Rocuronium Bromide Injection activity possible: Anticonvulsants. (7.2)
7.1 Antibiotics
7.1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as Rocuronium Bromide Injection include certain antibiotics (e.g., aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with Rocuronium Bromide Injection, prolongation of neuromuscular block may occur.
7.2 Anticonvulsants
7.2 Anticonvulsants In 2 of 4 patients who received chronic anticonvulsant therapy, apparent resistance to the effects of another rocuronium bromide injection product was observed in the form of diminished magnitude of neuromuscular block or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if Rocuronium Bromide Injection is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants.
While the mechanism for development of this resistance is not known, receptor up-regulation may be a contributing factor [see Warnings and Precautions (5.10)].
7.3 Inhalation Anesthetics
7.3 Inhalation Anesthetics Use of inhalation anesthetics (enflurane > isoflurane > halothane) has been shown to enhance the activity of other neuromuscular blocking agents. Isoflurane and enflurane may also prolong the duration of action of initial and maintenance doses of Rocuronium Bromide Injection and decrease the average infusion requirement of Rocuronium Bromide Injection by 40% compared to opioid/nitrous oxide/oxygen anesthesia.
No definite interaction between rocuronium bromide injection and halothane has been demonstrated. In one study, use of enflurane in 10 patients who received another rocuronium bromide injection product resulted in a 20% increase in mean clinical duration of the initial intubating dose, and a 37% increase in the duration of subsequent maintenance doses, when compared in the same study to 10 patients under opioid/nitrous oxide/oxygen anesthesia.
The clinical duration of initial doses of another rocuronium bromide injection product (0.57 mg/kg to 0.85 mg/kg) under enflurane or isoflurane anesthesia, as used clinically, was increased by 11% and 23%, respectively. The duration of maintenance doses was affected to a greater extent, increasing by 30% to 50% under either enflurane or isoflurane anesthesia.
Potentiation by these agents was also observed with respect to the infusion rates of rocuronium bromide injection required to maintain approximately 95% neuromuscular block. Under isoflurane and enflurane anesthesia, the infusion rates were decreased by approximately 40% compared to opioid/nitrous oxide/oxygen anesthesia.
The median spontaneous recovery time (from 25% to 75% of control T 1) was not affected by halothane but is prolonged by enflurane (15% longer) and isoflurane (62% longer). Reversal-induced recovery of Rocuronium Bromide Injection neuromuscular block is minimally affected by anesthetic technique [see Dosage and Administration (2.6) and Warnings and Precautions (5.10)].
7.4 Lithium Carbonate
7.4 Lithium Carbonate Lithium has been shown to increase the duration of neuromuscular block and decrease infusion requirements of neuromuscular blocking agents [see Warnings and Precautions (5.10)].
7.5 Local Anesthetics
7.5 Local Anesthetics Local anesthetics have been shown to increase the duration of neuromuscular block and decrease infusion requirements of neuromuscular blocking agents [see Warnings and Precautions (5.10)].
7.6 Magnesium
7.6 Magnesium Magnesium salts administered for the management of pre-eclampsia or eclampsia of pregnancy may enhance neuromuscular blockade [see Warnings and Precautions (5.10)].
7.7 Nondepolarizing Muscle Relaxants
7.7 Nondepolarizing Muscle Relaxants There are no controlled studies documenting the use of Rocuronium Bromide Injection before or after other nondepolarizing muscle relaxants. Interactions have been observed when other nondepolarizing muscle relaxants have been administered in succession.
7.8 Procainamide
7.8 Procainamide Procainamide has been shown to increase the duration of neuromuscular block and decrease infusion requirements of neuromuscular blocking agents [see Warnings and Precautions (5.10)].
7.9 Propofol
7.9 Propofol The use of propofol for induction and maintenance of anesthesia does not alter the clinical duration or recovery characteristics following recommended doses of Rocuronium Bromide Injection.
7.10 Quinidine
7.10 Quinidine Injection of quinidine during recovery from use of muscle relaxants is associated with recurrent paralysis. This possibility must also be considered for Rocuronium Bromide Injection [see Warnings and Precautions (5.10)].
7.11 Succinylcholine
7.11 Succinylcholine The use of Rocuronium Bromide Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. If Rocuronium Bromide Injection is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed.
The median duration of action of Rocuronium Bromide Injection 0.6 mg/kg administered after a 1 mg/kg dose of succinylcholine when T 1 returned to 75% of control was 36 minutes (range: 14-57, n=12) vs. 28 minutes (range: 17-51, n=12) without succinylcholine.
Adverse reactions
In clinical trials, the most common adverse reactions (2%) are transient hypotension and hypertension. The following adverse reactions are described, or described in greater detail, in other sections: Anaphylaxis [see Warnings and Precautions (5.2)] Residual paralysis [see Warnings and Precautions (5.5)] Myopathy [see Warnings and Precautions (5.6)] Increased pulmonary vascular resistance [see Warnings and Precautions (5.12)] Most common adverse reactions (2%) are transient hypotension and hypertension.
(6) To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Clinical studies of another rocuronium bromide injection product in the U.S.
(n=1137) and Europe (n=1394) totaled 2531 patients. The following adverse reactions were reported in patients administered another rocuronium bromide injection (all events judged by investigators during the clinical trials to have a possible causal relationship): Adverse reactions in greater than 1% of patients: None Adverse reactions in less than 1% of patients (probably related or relationship unknown): Cardiovascular: arrhythmia, abnormal electrocardiogram, tachycardia Digestive: nausea, vomiting Respiratory: asthma (bronchospasm, wheezing, or rhonchi), hiccup Skin and Appendages: rash, injection site edema, pruritus In the European studies of another rocuronium bromide injection product, the most commonly reported reactions were transient hypotension (2%) and hypertension (2%); these are in greater frequency than the US studies (0.1% and 0.1%).
Changes in heart rate and blood pressure were defined differently from in the US studies in which changes in cardiovascular parameters were not considered as adverse events unless judged by the investigator as unexpected, clinically significant, or thought to be histamine related. In a clinical study of another rocuronium bromide injection product in patients with clinically significant cardiovascular disease undergoing coronary artery bypass graft, hypertension and tachycardia were reported in some patients, but these occurrences were less frequent in patients receiving beta or calcium channel-blocking drugs.
In some patients, the use of another rocuronium bromide injection product was associated with transient increases (30% or greater) in pulmonary vascular resistance. In another clinical study of patients undergoing abdominal aortic surgery, transient increases (30% or greater) in pulmonary vascular resistance were observed in about 24% of patients who received another rocuronium bromide injection product at 0.6 mg/kg or 0.9 mg/kg.
In pediatric patient studies worldwide of another rocuronium bromide injection product (n=704), tachycardia occurred at an incidence of 5.3% (n=37), and it was judged by the investigator as related in 10 cases (1.4%).
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of rocuronium bromide injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Immune system disorders: In clinical practice, there have been reports of severe allergic reactions (anaphylactic reactions and shock) with rocuronium bromide injection, including some that have been life-threatening and fatal [see Warnings and Precautions (5.2)]. General disorders and administration site conditions: There have been reports of malignant hyperthermia with the use of rocuronium bromide injection [see Warnings and Precautions (5.7)].
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Available data from controlled trials and case series and over decades of use of rocuronium bromide in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There are potential risks when rocuronium bromide is used during labor or delivery (see Clinical Considerations).
Based on data from umbilical cord blood sampling, rocuronium bromide is transferred across the placenta [see Clinical Studies (14.1)]. In animal reproduction studies, there was no evidence of teratogenicity when rocuronium bromide was administered intravenously to pregnant, conscious, nonventilated rats and rabbits at 15% to 30% and 25%, respectively, the human intubation dose of 0.6 mg/kg to 1.2 mg/kg during the period of organogenesis (see Data).
The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Clinical Considerations Labor or Delivery: Magnesium sulfate used in the management of pre-eclampsia or eclampsia in pregnancy may enhance neuromuscular blockade [see Warning and Precautions 5.10]. The use of another rocuronium bromide injection product in Cesarean section has been studied in a limited number of patients.
Adverse events in this study included low APGAR scores in neonates at 5 minutes and poor intubation conditions in some pregnant women who received rocuronium bromide [see Clinical Studies (14.1)]. Rocuronium Bromide Injection is not recommended for rapid sequence induction in Cesarean section patients. Data Animal Data: Developmental toxicology studies have been performed with rocuronium bromide in pregnant, conscious, nonventilated rabbits and rats.
Inhibition of neuromuscular function was the endpoint for high-dose selection. The maximum tolerated dose served as the high dose and was administered intravenously 3 times a day to rats (0.3 mg/kg, 15% to 30% of human intubation dose of 0.6 mg/kg to 1.2 mg/kg based on the body surface unit of mg/m 2) from Day 6 to 17 and to rabbits (0.02 mg/kg, 25% human dose) from Day 6 to 18 of pregnancy.
High-dose treatment caused acute symptoms of respiratory dysfunction due to the pharmacological activity of the drug. Teratogenicity was not observed in these animal species. The incidence of late embryonic death was increased at the high dose in rats, most likely due to oxygen deficiency. Therefore, this finding probably has no relevance for humans because immediate mechanical ventilation of the intubated patient will effectively prevent embryo-fetal hypoxia.
Mechanism of action
12.1 Mechanism of Action Rocuronium Bromide Injection is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. It acts by competing for cholinergic receptors at the motor end-plate. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine and edrophonium.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics The Rocuronium Bromide Injection dose required to produce 95% suppression (ED 95) of the first [T 1] mechanomyographic [MMG] response of the adductor pollicis muscle [thumb] to indirect supramaximal train-of-four stimulation of the ulnar nerve) during opioid/nitrous oxide/oxygen anesthesia is approximately 0.3 mg/kg. Patient variability around the ED 95 dose suggests that 50% of patients will exhibit T 1 depression of 91% to 97%.
Table 4 presents intubating conditions in patients with intubation initiated at 60 to 70 seconds. Table 4: Percent of Excellent or Good Intubating Conditions and Median (Range) Time to Completion of Intubation in Patients with Intubation Initiated at 60 to 70 Seconds * Excludes patients undergoing Cesarean section. † Pediatric patients were under halothane anesthesia.
Excellent intubating conditions=jaw relaxed, vocal cords apart and immobile, no diaphragmatic movement. Good intubating conditions=same as excellent but with some diaphragmatic movement. rocuronium bromide injection Dose (mg/kg) Administered Over 5 sec Percent of Patients with Excellent or Good Intubating Conditions Time to Completion of Intubation (min) Adults* 18 to 64 yrs 0.45 (n=43) 0.6 (n=51) 86% 96% 1.6 (1.0-7.0) 1.6 (1.0-3.2) Infants † 3 mo to 1 yr 0.6 (n=18) 100% 1.0 (1.0-1.5) Pediatric † 1 to 12 yrs 0.6 (n=12) 100% 1.0 (0.5-2.3) Table 5 presents the time to onset and clinical duration for the initial dose of Rocuronium Bromide Injection under opioid/nitrous oxide/oxygen anesthesia in adults and geriatric patients, and under halothane anesthesia in pediatric patients.
Table 5: Median (Range) Time to Onset and Clinical Duration Following Initial (Intubating) Dose During Opioid/Nitrous Oxide/Oxygen Anesthesia (Adults) and Halothane Anesthesia (Pediatric Patients) n=the number of patients who had time to maximum block recorded. Clinical duration=time until return to 25% of control T 1. Patients receiving doses of 0.45 mg/kg who achieved less than 90% block (16% of these patients) had about 12 to 15 minutes to 25% recovery. rocuronium bromide injection Dose (mg/kg) Administered Over 5 sec Time to ≥80% Block (min) Time to Maximum Block (min) Clinical Duration (min) Adults 18 to 64 yrs 1.3 (0.8-6.2) 3.0 (1.3-8.2) 22 (12-31) 0.45 (n=50) 0.6 (n=142) 1.0 (0.4-6.0) 1.8 (0.6-13.0) 31 (15-85) 0.9 (n=20) 1.1 (0.3-3.8) 1.4 (0.8-6.2) 58 (27-111) 1.2 (n=18) 0.7 (0.4-1.7) 1.0 (0.6-4.7) 67 (38-160) Geriatric ≥65 yrs 2.3 (1.0-8.3) 3.7 (1.3-11.3) 46 (22-73) 0.6 (n=31) 0.9 (n=5) 2.0 (1.0-3.0) 2.5 (1.2-5.0) 62 (49-75) 1.2 (n=7) 1.0 (0.8-3.5) 1.3 (1.2-4.7) 94 (64-138) Infants 3 mo to 1 yr 0.6 (n=17) 0.8 (n=9) — — 0.8 (0.3-3.0) 0.7 (0.5-0.8) 41 (24-68) 40 (27-70) Pediatric 1 to 12 yrs 0.6 (n=27) 0.8 (n=18) 0.8 (0.4-2.0) — 1.0 (0.5-3.3) 0.5 (0.3-1.0) 26 (17-39) 30 (17-56) Table 6 presents the time to onset and clinical duration for the initial dose of Rocuronium Bromide Injection (rocuronium bromide) Injection under sevoflurane (induction) and isoflurane/nitrous oxide (maintenance) anesthesia in pediatric patients.
Table 6: Median (Range) Time to Onset and Clinical Duration Following Initial (Intubating) Dose During Sevoflurane (induction) and Isoflurane/Nitrous Oxide (maintenance) Anesthesia (Pediatric Patients) n=the number of patients with the highest number of observations for time to maximum block or reappearance T 3. rocuronium bromide injection Dose (mg/kg) Administered Over 5 sec Time to Maximum Block (min) Time to Reappearance T 3 (min) Neonates birth to <28 days 1.1 (0.6-2.2) 40.3 (32.5-62.6) 0.45 (n=5) 0.6 (n=10) 1.0 (0.2-2.1) 49.7 (16.6-119.0) 1 (n=6) 0.6 (0.3-1.8) 114.4 (92.6-136.3) Infants 28 days to ≤3 mo 0.5 (0.4-1.3) 49.1 (13.5-79.9) 0.45 (n=9) 0.6 (n=11) 0.4 (0.2-0.8) 59.8 (32.3-87.8) 1 (n=5) 0.3 (0.2-0.7) 103.3 (90.8-155.4) Toddlers >3 mo to ≤2 yrs 0.8 (0.3-1.9) 39.2 (16.9-59.4) 0.45 (n=17) 0.6 (n=29) 0.6 (0.2-1.6) 44.2 (18.9-68.8) 1 (n=15) 0.5 (0.2-1.5) 72.0 (36.2-128.2) Children >2 yrs to ≤11 yrs 0.9 (0.4-1.9) 21.5 (17.5-38.0) 0.45 (n=14) 0.6 (n=37) 0.8 (0.3-1.7) 36.7 (20.1-65.9) 1 (n=16) 0.7 (0.4-1.2) 53.1 (31.2-89.9) Adolescents >11 to ≤17 yrs 1.0 (0.5-1.7) 37.5 (18.3-65.7) 0.45 (n=18) 0.6 (n=31) 0.9 (0.2-2.1) 41.4 (16.3-91.2) 1 (n=14) 0.7 (0.5-1.2) 67.1 (25.6-93.8) The time to 80% or greater block and clinical duration as a function of dose are presented in Figures 1 and 2. Figure 1: Time to 80% or Greater Block vs.
Initial Dose of rocuronium bromide injection by Age Group (Median, 25th and 75th Percentile, and Individual Values) Figure 2: Duration of Clinical Effect vs. Initial Dose of rocuronium bromide injection by Age Group (Median, 25th and 75th Percentile, and Individual Values) The clinical durations for the first 5 maintenance doses, in patients receiving 5 or more maintenance doses are represented in Figure 3 [see Dosage and Administration (2.4)].
Figure 3: Duration of Clinical Effect vs. Number of rocuronium bromide injection Maintenance Doses, by Dose Once spontaneous recovery has reached 25% of control T 1, the neuromuscular block produced by rocuronium bromide injection is readily reversed with anticholinesterase agents, e.g., edrophonium or neostigmine. The median spontaneous recovery from 25% to 75% T 1 was 13 minutes in adult patients.
When neuromuscular block was reversed in 36 adults at a T 1 of 22% to 27%, recovery to a T 1 of 89 (50-132)% and T 4 /T 1 of 69 (38-92)% was achieved within 5 minutes. Only 5 of 320 adults reversed received an additional dose of reversal agent. The median (range) dose of neostigmine was 0.04 (0.01-0.09) mg/kg and the median (range) dose of edrophonium was 0.5 (0.3-1.0) mg/kg.
In geriatric patients (n=51) reversed with neostigmine, the median T 4 /T 1 increased from 40% to 88% in 5 minutes. In clinical trials with halothane, pediatric patients (n=27) who received 0.5 mg/kg edrophonium had increases in the median T 4 /T 1 from 37% at reversal to 93% after 2 minutes. Pediatric patients (n=58) who received 1 mg/kg edrophonium had increases in the median T 4 /T 1 from 72% at reversal to 100% after 2 minutes.
Infants (n=10) who were reversed with 0.03 mg/kg neostigmine recovered from 25% to 75% T 1 within 4 minutes. There were no reports of less than satisfactory clinical recovery of neuromuscular function. The neuromuscular blocking action of Rocuronium Bromide Injection may be enhanced in the presence of potent inhalation anesthetics [see Drug Interactions (7.3)].
Figure 1 Figure 2 Figure 3 Hemodynamics There were no dose-related effects on the incidence of changes from baseline (30% or greater) in mean arterial blood pressure (MAP) or heart rate associated with rocuronium bromide injection administration over the dose range of 0.12 mg/kg to 1.2 mg/kg (4 x ED 95) within 5 minutes after rocuronium bromide injection administration and prior to intubation. Increases or decreases in MAP were observed in 2% to 5% of geriatric and other adult patients, and in about 1% of pediatric patients.
Heart rate changes (30% or greater) occurred in 0% to 2% of geriatric and other adult patients. Tachycardia (30% or greater) occurred in 12 of 127 pediatric patients. Most of the pediatric patients developing tachycardia were from a single study where the patients were anesthetized with halothane and who did not receive atropine for induction [see Clinical Studies (14.3)].
In US studies, laryngoscopy and tracheal intubation following rocuronium bromide injection administration were accompanied by transient tachycardia (30% or greater increases) in about one-third of adult patients under opioid/nitrous oxide/oxygen anesthesia. Animal studies have indicated that the ratio of vagal:neuromuscular block following Rocuronium Bromide Injection administration is less than vecuronium but greater than pancuronium.
The tachycardia observed in some patients may result from this vagal blocking activity. Histamine Release In studies of histamine release, clinically significant concentrations of plasma histamine occurred in 1 of 88 patients. Clinical signs of histamine release (flushing, rash, or bronchospasm) associated with the administration of Rocuronium Bromide Injection were assessed in clinical trials and reported in 9 of 1137 (0.8%) patients.
Pharmacokinetics
The rapid distribution half-life is 1 to 2 minutes and the slower distribution half-life is 14 to 18 minutes.
Table 7: Mean (SD) Pharmacokinetic Parameters in Adults (n=22; ages 27 to 58 yrs) and Geriatric (n=20; 65 yrs or greater) During Opioid/Nitrous Oxide/Oxygen Anesthesia PK Parameters Adults (Ages 27-58 yrs) Geriatrics (≥65 yrs) Clearance (L/kg/hr) 0.25 (0.08) 0.21 (0.06) Volume of Distribution at Steady State (L/kg) 0.25 (0.04) 0.22 (0.03) t1/2 β Elimination (hr) 1.4 (0.4) 1.5 (0.4) In general, studies with normal adult subjects did not reveal any differences in the pharmacokinetics of rocuronium due to gender.
Studies of distribution, metabolism, and excretion in cats and dogs indicate that rocuronium is eliminated primarily by the liver.
In general, patients undergoing cadaver kidney transplant have a small reduction in clearance which is offset pharmacokinetically by a corresponding increase in volume, such that the net effect is an unchanged plasma half-life.
PK Parameters Normal Renal and Hepatic Function Renal Transplant Patients Hepatic Dysfunction Patients Clearance (L/kg/hr) 0.16 (0.05)* 0.13 (0.04) 0.13 (0.06) Volume of Distribution at Steady State (L/kg) 0.26 (0.03) 0.34 (0.11) 0.53 (0.14) t1/2 β Elimination (hr) 2.4 (0.8)* 2.4 (1.1) 4.3 (2.6) The net result of these findings is that subjects with renal failure have clinical durations that are similar to but somewhat more variable than the duration that one would expect in subjects with normal renal function.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Adult and Geriatric Patients In an effort to maximize the information gathered in the in vivo pharmacokinetic studies, the data from the studies was used to develop population estimates of the parameters for the subpopulations represented (e.g., geriatric, pediatric, renal, and hepatic impairment). These population-based estimates and a measure of the estimate variability are contained in the following section.
Following intravenous administration of rocuronium bromide injection, plasma levels of rocuronium follow a three-compartment open model. The rapid distribution half-life is 1 to 2 minutes and the slower distribution half-life is 14 to 18 minutes. Rocuronium is approximately 30% bound to human plasma proteins. In geriatric and other adult surgical patients undergoing either opioid/nitrous oxide/oxygen or inhalational anesthesia, the observed pharmacokinetic profile was essentially unchanged [see Dosage and Administration (2.6)].
Table 7: Mean (SD) Pharmacokinetic Parameters in Adults (n=22; ages 27 to 58 yrs) and Geriatric (n=20; 65 yrs or greater) During Opioid/Nitrous Oxide/Oxygen Anesthesia PK Parameters Adults (Ages 27-58 yrs) Geriatrics (≥65 yrs) Clearance (L/kg/hr) 0.25 (0.08) 0.21 (0.06) Volume of Distribution at Steady State (L/kg) 0.25 (0.04) 0.22 (0.03) t1/2 β Elimination (hr) 1.4 (0.4) 1.5 (0.4) In general, studies with normal adult subjects did not reveal any differences in the pharmacokinetics of rocuronium due to gender. Studies of distribution, metabolism, and excretion in cats and dogs indicate that rocuronium is eliminated primarily by the liver.
The rocuronium analog 17-desacetyl-rocuronium, a metabolite, has been rarely observed in the plasma or urine of humans administered single doses of 0.5 mg/kg to 1 mg/kg with or without a subsequent infusion (for up to 12 hr) of rocuronium. In the cat, 17-desacetyl-rocuronium has approximately one-twentieth the neuromuscular blocking potency of rocuronium.
The effects of renal failure and hepatic disease on the pharmacokinetics and pharmacodynamics of rocuronium in humans are consistent with these findings. In general, patients undergoing cadaver kidney transplant have a small reduction in clearance which is offset pharmacokinetically by a corresponding increase in volume, such that the net effect is an unchanged plasma half-life.
Patients with demonstrated liver cirrhosis have a marked increase in their volume of distribution resulting in a plasma half- life approximately twice that of patients with normal hepatic function. Table 8 shows the pharmacokinetic parameters in subjects with either impaired renal or hepatic function. Table 8: Mean (SD) Pharmacokinetic Parameters in Adults with Normal Renal and Hepatic Function (n=10, ages 23 to 65), Renal Transplant Patients (n=10, ages 21 to 45), and Hepatic Dysfunction Patients (n=9, ages 31 to 67) During Isoflurane Anesthesia * Differences in the calculated t 1/2 β and Cl between this study and the study in young adults vs. geriatrics (≥65 years) is related to the different sample populations and anesthetic techniques.
PK Parameters Normal Renal and Hepatic Function Renal Transplant Patients Hepatic Dysfunction Patients Clearance (L/kg/hr) 0.16 (0.05)* 0.13 (0.04) 0.13 (0.06) Volume of Distribution at Steady State (L/kg) 0.26 (0.03) 0.34 (0.11) 0.53 (0.14) t1/2 β Elimination (hr) 2.4 (0.8)* 2.4 (1.1) 4.3 (2.6) The net result of these findings is that subjects with renal failure have clinical durations that are similar to but somewhat more variable than the duration that one would expect in subjects with normal renal function. Hepatically impaired patients, due to the large increase in volume, may demonstrate clinical durations approaching 1.5 times that of subjects with normal hepatic function.
In both populations the clinician should individualize the dose to the needs of the patient [see Dosage and Administration (2.6)]. Tissue redistribution accounts for most (about 80%) of the initial amount of rocuronium administered. As tissue compartments fill with continued dosing (4-8 hours), less drug is redistributed away from the site of action and, for an infusion-only dose, the rate to maintain neuromuscular blockade falls to about 20% of the initial infusion rate.
The use of a loading dose and a smaller infusion rate reduces the need for adjustment of dose. Pediatric Patients Under halothane anesthesia, the clinical duration of effects of rocuronium bromide injection did not vary with age in patients 4 months to 8 years of age. The terminal half-life and other pharmacokinetic parameters of rocuronium in these pediatric patients are presented in Table 9.
Table 9: Mean (SD) Pharmacokinetic Parameters of Rocuronium in Pediatric Patients (ages 3 to less than 12 mos, n=6; 1 to less than 3 yrs, n=5; 3 to less than 8 yrs, n=7) During Halothane Anesthesia PK Parameters Patient Age Range 3 to <12 mos 1 to <3 yrs 3 to <8 yrs Clearance (L/kg/hr) 0.35 (0.08) 0.32 (0.07) 0.44 (0.16) Volume of Distribution at Steady State (L/kg) 0.30 (0.04) 0.26 (0.06) 0.21 (0.03) t1/2 β Elimination (hr) 1.3 (0.5) 1.1 (0.7) 0.8 (0.3) Pharmacokinetics of rocuronium bromide injection were evaluated using a population analysis of the pooled pharmacokinetic datasets from 2 trials under sevoflurane (induction) and isoflurane/nitrous oxide (maintenance) anesthesia. All pharmacokinetic parameters were found to be linearly proportional to body weight.
In patients under the age of 18 years, clearance (CL) and volume of distribution (Vss) increase with bodyweight (kg) and age (years). As a result, the terminal half-life of rocuronium bromide injection decreases with increasing age from 1.1 hour to 0.7-0.8 hour. Table 10 presents the pharmacokinetic parameters in the different age groups in the studies with sevoflurane (induction) and isoflurane/nitrous oxide (maintenance) anesthesia.
Table 10: Mean (SD) Pharmacokinetic Parameters of Rocuronium in Pediatric Patients During Sevoflurane (induction) and Isoflurane/Nitrous Oxide (maintenance) Anesthesia PK Parameters Patient Age Range Birth to <28 days 28 days to ≤3 mos 3 mos to ≤2 yrs 2 to ≤11 yrs 11 to ≤17 yrs CL (L/kg/hr) 0.31 (0.07) 0.30 (0.08) 0.33 (0.10) 0.35 (0.09) 0.29 (0.14) Volume of Distribution (L/kg) 0.42 (0.06) 0.31 (0.03) 0.23 (0.03) 0.18 (0.02) 0.18 (0.01) t1/2 β (hr) 1.1 (0.2) 0.9 (0.3) 0.8 (0.2) 0.7 (0.2) 0.8 (0.3)
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Rocuronium 10 mg/mL, 5 mL Ampule | ₱149.88–₱214.44Reference ₱149.88 | per ampule | DPRI procurement range |
| Rocuronium 10 mg/mL, 5 mL Vial | ₱149.33–₱250.00Reference ₱158.60 | per vial | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Rocuronium (as bromide) |
| PNF listing | Inj.: 10 mg/mL, 5 mL ampul/vial (IV)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Rocuronium · Fresenius Kabi USA, LLC [US FDA-approved label, version 1, August 2, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04c9812d-5aa3-4949-ad02-c618028f1bb0
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .